Scientists believe they may have found the trigger behind the extremely rare blood clot complications linked to the Oxford/AstraZeneca vaccine. The UK government has ordered around 100,000 doses of the drug. The Medicines and Healthcare products Regulatory Agency has authorised the therapy for people with mild to moderate covid-19 who are at high risk of developing severe disease. Clinical trial results found that Xevudy (sotrovimab) cuts hospital admission and death by 79 per cent in people at high risk. The company says initial tests in the lab suggest that it works against the omicron variant. The UK has approved a new antibody-based drug treatment for covid-19 made by GlaxoSmithKline.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |